DGAP-News: Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum Phosphorus an
(firmenpresse) - Keryx Biopharmaceuticals, Inc.
04.11.2013 23:00
---------------------------------------------------------------------------
Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at
8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of
Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum
Phosphorus and Iron Deficiency Anemia
NEW YORK, 2013-11-04 23:00 CET (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals,
Inc. (Nasdaq:KERX) will host a conference call tomorrow, Tuesday, November 5,
2013, at 8:30am ET to review the top-line results from the Phase 2 study of
Zerenex(tm) (ferric citrate coordination complex) in non-dialysis dependent
chronic kidney disease patients with elevated serum phosphorus and iron
deficiency anemia. Keryx will announce the top-line results tomorrow morning,
prior to the call.
Ron Bentsur, Chief Executive Officer of Keryx, will host the call. Geoffrey A.
Block, MD, Director of Clinical Research at Denver Nephrology, Glenn Chertow,
MD, Chief, Division of Nephrology and Professor of Medicine at Stanford
University School of Medicine, and Steven Fishbane, MD, Chief, Division of
Nephrology, Vice President of North Shore-LIJ Health System for Network
Dialysis Services and Director of Clinical Research at North Shore-LIJ
Department of Medicine, Co-Chairmen of the Phase 2 study, will also join the
call.
In addition to the announcement of the top-line results, the Company will
briefly discuss the Company's third quarter financial results and provide a
business outlook for the remainder of 2013.
In order to participate in the conference call, please call 1-877-869-3847
(U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The rebroadcast
of the conference call will be available for replay at http://www.keryx.com,
for a period of 15 days after the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate
coordination complex), an oral, ferric iron-based compound that has the
capacity to bind to phosphate and form non-absorbable complexes. Keryx has
completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment
of hyperphosphatemia (elevated phosphate levels) in patients with chronic
kidney disease on dialysis, conducted pursuant to a Special Protocol Assessment
(SPA) agreement with the Food and Drug Administration (FDA). The Company's New
Drug Application (NDA) is currently under review by the FDA with an assigned
Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014. The Marketing
Authorization Application filing with the European Medicines Agency (EMA) is
pending submission. The Company is also developing Zerenex in the U.S. for the
management of elevated phosphorus and iron deficiency anemia in patients with
stages 3 to 5 non-dialysis dependent chronic kidney disease. In addition,
Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.
has filed its New Drug Application for marketing approval of ferric citrate in
Japanfor the treatment of hyperphosphatemia in patients with chronic kidney
disease. Keryx is headquartered in New York City.
CONTACT: Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer(at)keryx.com
News Source: NASDAQ OMX
04.11.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Keryx Biopharmaceuticals, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US4925151015
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
keryx-biopharmaceuticals-to-hold-conference-call-tomorrow
november-5
2013
at-8-30am-et-to-discuss-top
line-results-from-zerenex-tm-phase-2-study-of-non
dialysis-dependent-chronic-kidney-disease-patients-with-elevated-serum-phosphorus-an
Unternehmensinformation / Kurzprofil:
Datum: 04.11.2013 - 23:00 Uhr
Sprache: Deutsch
News-ID 312516
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 309 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum Phosphorus an"
steht unter der journalistisch-redaktionellen Verantwortung von
Keryx Biopharmaceuticals, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
